What is the recommended treatment for Erysipelas (erysipelas)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Erysipelas

Penicillin is the treatment of choice for erysipelas, administered orally for uncomplicated cases or parenterally for severe infections, for 5-10 days. 1

First-Line Treatment Options

  • For uncomplicated cases, oral penicillin V 500 mg every 6-8 hours for 5-7 days is recommended as first-line treatment 1, 2
  • Amoxicillin 500 mg three times daily for 5-7 days is an effective alternative oral treatment 1
  • For more severe cases requiring hospitalization, intravenous penicillin G is recommended, typically 12-24 million units/day divided every 4-6 hours 3
  • Treatment duration of 5-7 days is as effective as 10 days for uncomplicated cases if clinical improvement is observed 1

Alternative Treatment Options for Penicillin Allergy

  • Clindamycin (300-450 mg orally three times daily or 600 mg IV every 8 hours) is the preferred alternative for patients with severe penicillin allergy 1
  • Erythromycin (250 mg four times daily) may be used, though there is risk of resistance in some streptococcal strains 1
  • Vancomycin IV (30 mg/kg/day in 2 divided doses) is another effective alternative for severe cases with penicillin allergy 1

Special Considerations

  • Empiric therapy for community-acquired MRSA should be considered for patients at risk for CA-MRSA or who do not respond to first-line therapy 4, 1
  • Blood cultures have low diagnostic yield (positive in only 3% of cases) and are generally not necessary for typical cases of erysipelas 1, 5
  • Erysipelas is primarily caused by streptococci, especially Streptococcus pyogenes, so any second-line antibiotic should have good coverage against these microorganisms 4, 1

Adjunctive Measures

  • Elevation of the affected area to promote gravity drainage of edema and inflammatory substances 1
  • Treatment of potential entry points such as athlete's foot, eczema, or trauma sites 1
  • In uncomplicated cases, systemic corticosteroids may be considered as adjunctive treatment to accelerate symptom resolution 1
  • Other helpful adjunctive measures include anticoagulation, non-steroidal anti-inflammatory agents, and appropriate dressings 6

Prevention of Recurrences

  • Treating predisposing conditions (athlete's foot, venous eczema, lymphedema) is essential to prevent recurrences 1
  • Maintaining well-hydrated skin with emollients helps prevent recurrent infections 1
  • Reducing underlying edema through elevation of the limb, compression stockings, or pneumatic pressure pumps 1
  • Prophylactic antibiotic therapy with delayed penicillin is recommended for recurrent erysipelas 7

Clinical Pearls and Pitfalls

  • Penicillin remains the gold standard treatment with shorter duration of fever after treatment initiation compared to other antibiotics 8
  • Avoid confusing erysipelas with other forms of cellulitis or skin infections that may require different treatment approaches 1
  • Avoid prolonging antibiotic treatment beyond what is necessary for uncomplicated cases 1
  • Studies have shown no advantage in using antibiotics other than penicillin for treating typical erysipelas 5

References

Guideline

Erisipela Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Antibiotic use in patients with erysipelas: a retrospective study.

The Israel Medical Association journal : IMAJ, 2001

Research

[Treatment of erysipelas in Germany and Austria--results of a survey in German and Austrian dermatological clinics].

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2005

Research

Analysis of epidemiology, clinical features and management of erysipelas.

International journal of dermatology, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.